2-phenoxy-1-(thiazol-2-yl)ethanone | 1621517-45-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-phenoxy-1-(thiazol-2-yl)ethanone
• 英文别名: 2-Phenoxy-1-(1,3-thiazol-2-yl)ethanone；2-phenoxy-1-(1,3-thiazol-2-yl)ethanone
• CAS: 1621517-45-0
• 化学式: C₁₁H₉NO₂S
• 分子量: 219.264
• InChiKey: WOOYEWBJUHBQGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  苯氧乙酸 在 lithium chloro-isopropyl-magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 4.55h， 生成 2-phenoxy-1-(thiazol-2-yl)ethanone
  参考文献：
  名称：

  由苯并噻唑/噻唑和N，N'-羰基二咪唑活化的羧酸方便地合成2-酰基苯并噻唑/噻唑

  摘要：

  已经开发了一种方便有效的合成2-酰基苯并噻唑/噻唑的策略。用烯丙基格利雅试剂处理苯并噻唑/噻唑容易产生相应的2-格利雅试剂，然后与N，N′-羰基二咪唑活化的羧酸反应，得到各种2-酰基苯并噻唑/噻唑产物。该合成方法适用于多种羧酸，并且在温和的反应条件下，可以很容易地获得2-酰基苯并噻唑/噻唑。

  DOI：

  10.1016/j.tetlet.2019.05.043

文献信息

• [EN] ANTIINFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS<br/>[FR] COMPOSÉS 2-OXOTHIAZOLES ET 2-OXOTHIOPHÈNES ANTI-INFLAMMATOIRES ET ANTITUMORAUX
  申请人：AVEXXIN AS

  公开号：WO2014118195A1

  公开（公告）日：2014-08-07

  A compound of formula (I) wherein X is O, C O or S; Y is N or CH; R2 and R4 are each independently H, -(CH2)pCOOH, -(CH2)pCON(R5)2 or - (CH2)pCOOC 1-6alkyI; or R2 and R4 together form a 6-membered phenyl ring fused to the five membered ring; each R1 is independently selected from H, halo (e.g. fluoro or chloro), C6-10aryl, C7-12arylalkyl, C2-12alkenyl; OC1-2 alkyl, OC2-12 aikenyl or a C1-12 alkyl group; each R5 is H or C1-6 alkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof.

  式（I）的化合物，其中X为O、CO或S；Y为N或CH；R2和R4分别独立地为H、-(CH2)pCOOH、-(CH2)pCON(R5)2或-(CH2)pCOOC 1-6alkyI；或R2和R4一起形成与五元环融合的六元苯环；每个R1独立地选自H、卤素（例如氟或氯）、C6-10芳基、C7-12芳基烷基、C2-12烯基；OC1-2烷基、OC2-12烯基或C1-12烷基基团；每个R5为H或C1-6烷基；每个p为0至3；n为1至4；或其盐、酯、溶剂化合物、N-氧化物或前药，例如其盐。
• ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS
  申请人：AVEXXIN AS

  公开号：US20150376161A1

  公开（公告）日：2015-12-31

  A compound of formula (I) wherein X is O, C═O or S; Y is N or CH; R 2 and R 4 are each independently H, —(CH 2 ) p COOH, —(CH 2 ) p CON(R 5 ) 2 or —(CH 2 ) p COOC 1-6 alkyl; or R 2 and R 4 together form a 6-membered phenyl ring fused to the five membered ring; each R 1 is independently selected from H, halo (e.g. fluoro or chloro), C 6-10 aryl, C 7-12 arylalkyl, C 2-12 alkenyl; OC 1-12 alkyl, OC 2-12 alkenyl or a C 1-12 alkyl group; each R 5 is H or C 1-6 alkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof

  化合物的式子(I)，其中X是O，C═O或S;Y是N或CH;R2和R4各自独立地为H，—(CH2)pCOOH，—(CH2)pCON(R5)2或—(CH2)pCOOC1-6烷基;或者R2和R4共同形成一个6成员苯环融合到五成员环上;每个R1独立地选自H，卤素（例如氟或氯），C6-10芳基，C7-12芳基烷基，C2-12烯丙基;OC1-12烷基，OC2-12烯丙基或C1-12烷基;每个R5是H或C1-6烷基;每个p为0到3;n为1到4;或其盐，酯，溶剂化物，N-氧化物或前药，例如其盐。
• Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds
  申请人：Avexxin AS

  公开号：US10259801B2

  公开（公告）日：2019-04-16

  A compound of formula (I) wherein X is O, C═O or S; Y is N or CH; R2 and R4 are each independently H, —(CH2)pCOOH, —(CH2)pCON(R5)2 or —(CH2)pCOOC1-6alkyl; or R2 and R4 together form a 6-membered phenyl ring fused to the five membered ring; each R1 is independently selected from H, halo (e.g. fluoro or chloro), C6-10aryl, C7-12arylalkyl, C2-12 alkenyl; OC1-12 alkyl, OC2-12 alkenyl or a C1-12 alkyl group; each R5 is H or C1-6 alkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof.

  式 (I) 的化合物 其中 X 是 O、C═O 或 S； Y 是 N 或 CH； R2 和 R4 各自独立地为 H、-(CH2)pCOOH、-(CH2)pCON(R5)2 或 -(CH2)pCOOC1-6烷基；或 R2 和 R4 共同形成与五元环融合的六元苯基环； 每个 R1 独立选自 H、卤代物（如氟或氯）、C6-10 芳基、C7-12 芳烷基、C2-12 烯基、OC1-12 烷基、OC2-12 烯基或 C1-12 烷基； 每个 R5 是 H 或 C1-6 烷基 每个 p 是 0 至 3 n 为 1 至 4； 或其盐、酯、溶液、N-氧化物或原药，例如其盐。
• 2-oxothiatole compounds having activity as cPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders
  申请人：Avexxin AS

  公开号：US10851114B2

  公开（公告）日：2020-12-01

  A compound of formula (I′) wherein R6 is H, C1-6alkyl, —(CH2)pCOOH, —(CH2)pCOOC1-6alkyl, —(CH2)pCONH2, —(CH2)pCONHC1-6alkyl, —(CH2)pCON(C1-6alkyl)2, R7 is as defined for R6; or and R7 taken together with the atoms joining them can form a 6-membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g. O, N or S containing) ring optionally substituted by up to 4 groups R8; each R8 is defined as for R6 or is oxo; R10 is C1-6alkyl Ar is a C6-14 aryl group, wherein the aryl group may be optionally substituted (preferably in the meta or para position relative to O) with one or more R9 groups; each R9 is halo, OH, CN, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, haloC1-6alkyl, C6-10 aryl group, C7-12 arylalkyl, a C1-10alkyl group, C2-10-mono or multiply unsaturated alkenyl group, OC1-10alkyl group, SC1-10alkyl group —OC1-10alkyl-O—C10alkyl, —C1-10alkyl-O—C1-10alkyl, —OC2-10-mono or multiply unsaturated alkenyl group, OAr2, O(CH2)qAr2, SAr2 or S(CH2)qAr2; wherein Ar2 is phenyl, optionally substituted with one or more of halo, trihalomethyl, C1-10-alkoxy, or C1-10 alkyl; each q is 1 to 3, preferably 1; each p is 0 to 3; or a salt, ester, solvate, N-oxide, or prodrug thereof.

  式(I′)化合物 其中R6为H、C1-6烷基、-(CH2)pCOOH、-(CH2)pCOOC1-6烷基、-(CH2)pCONH2、-(CH2)pCONHC1-6烷基、-(CH2)pCON(C1-6烷基)2，R7如R6所定义；或R7与连接它们的原子一起可形成6元芳香或非芳香、饱和或不饱和、碳环或含杂原子(如含O、N或S)的环；每个R8如R6所定义或为氧代；R10为C1-6烷基R10 是 C1-6 烷基 Ar 是 C6-14 芳基，其中芳基可任选被一个或多个 R9 基团取代（最好在相对于 O 的元或对位）；每个 R9 是卤代、OH、CN、硝基、NH2、NHC1-6烷基、N(C1-6烷基)2、卤代 C1-6烷基、C6-10 芳基、C7-12 芳烷基、C1-10 烷基、C2-10 单或多不饱和烯基OC1-10-烷基、SC1-10-烷基、-OC1-10-烷基-O-C10-烷基、-C1-10-烷基-O-C1-10-烷基、-OC2-10-单基或多重不饱和烯基、OAr2、O(CH2)qAr2、SAr2 或 S(CH2)qAr2；其中 Ar2 是苯基，任选被卤代、三卤甲基、C1-10-烷氧基或 C1-10 烷基中的一个或多个取代；每个 q 是 1 至 3，优选 1；每个 p 是 0 至 3；或其盐、酯、溶液、N-氧化物或原药。
• Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
  申请人：Avexxin AS

  公开号：US11034666B2

  公开（公告）日：2021-06-15

  A compound of formula (I) wherein X is O, C═O or S; Y is N or CH; R2 and R4 are each independently H, —(CH2)pCOOH, —(CH2)pCON(R5)2 or —(CH2)pCOOC1-6alkyl; or R2 and R4 together form a 6-membered phenyl ring fused to the five membered ring; each R1 is independently selected from H, halo (e.g. fluoro or chloro), C6-10aryl, C7-12arylalkyl, C2-12 alkenyl; OC1-12 alkyl, OC2-12 alkenyl or a C1-12 alkyl group; each R5 is H or C1-6 alkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof.

  式 (I) 的化合物 其中 X 是 O、C═O 或 S； Y 是 N 或 CH； R2 和 R4 各自独立地为 H、-(CH2)pCOOH、-(CH2)pCON(R5)2 或 -(CH2)pCOOC1-6烷基；或 R2 和 R4 共同形成与五元环融合的六元苯基环； 每个 R1 独立选自 H、卤代物（如氟或氯）、C6-10 芳基、C7-12 芳烷基、C2-12 烯基、OC1-12 烷基、OC2-12 烯基或 C1-12 烷基； 每个 R5 是 H 或 C1-6 烷基 每个 p 是 0 至 3 n 为 1 至 4； 或其盐、酯、溶液、N-氧化物或原药，例如其盐。